New Triple Receptor Agonist UBT251 Drives Nearly 20% Weight Loss in 24 Weeks
A phase 2 trial finds UBT251, targeting GLP-1, GIP, and glucagon receptors, cuts body weight by up to 19.7% — with broad cardiometabolic gains.
Summary
UBT251 is a next-generation weight-loss drug that activates three hormonal receptors simultaneously — GLP-1, GIP, and glucagon — to drive fat loss and improve metabolic health. In a 24-week randomized controlled trial involving 205 adults with overweight or obesity but without type 2 diabetes, participants receiving weekly UBT251 injections lost between 13.6% and 19.7% of their body weight, compared to just 2.0% in the placebo group. Beyond weight loss, the drug improved waist circumference, BMI, blood pressure, cholesterol levels, and blood sugar markers. Side effects were primarily mild-to-moderate gastrointestinal symptoms, consistent with other drugs in this class. These results position UBT251 as a strong candidate for phase 3 development and potentially one of the most effective obesity drugs tested to date.
Detailed Summary
Obesity is one of the most potent accelerants of biological aging, driving cardiovascular disease, insulin resistance, cancer risk, and cognitive decline. Drugs that produce substantial, sustained fat loss — particularly with cardiometabolic benefits — therefore represent a genuine longevity intervention. UBT251 targets this problem through an unprecedented triple-receptor approach.
This multicenter, randomized, double-blind, placebo-controlled phase 2 trial enrolled 205 adults in China with overweight or obesity but without type 2 diabetes. Participants were aged 18 to 61 years; 59% were women. They received once-weekly subcutaneous injections of UBT251 at doses of 2 mg, 4 mg (with either a 0.5 mg or 1 mg starting dose), or 6 mg, or placebo for 24 weeks.
The primary efficacy endpoint — least-squares mean percentage change in body weight at week 24 — was striking. UBT251 groups lost between 13.6% and 19.7% of body weight, versus just 2.0% for placebo. Placebo-adjusted differences ranged from -11.5% to -17.7%, all reaching p < 0.001. Beyond weight, UBT251 significantly improved waist circumference, BMI, systolic and diastolic blood pressure, lipid profiles, and glycemic parameters — a broad cardiometabolic improvement package rarely seen at this magnitude. The most frequent adverse events were mild-to-moderate gastrointestinal symptoms, the signature side effect of GLP-1-class drugs.
UBT251's triple mechanism — combining GLP-1 (appetite suppression and insulin secretion), GIP (enhanced insulin response and fat metabolism), and glucagon (energy expenditure and fat oxidation) — may explain its superior efficacy compared to dual agonists like tirzepatide. The glucagon component in particular could drive additional thermogenesis and lipolysis beyond what GLP-1/GIP combinations achieve.
Caveats include the short 24-week duration, a Chinese trial population limiting generalizability, and the abstract-only availability of this summary. Industry co-funding and Novo Nordisk author involvement warrant acknowledgment. Phase 3 trials are needed to confirm durability and long-term safety.
Key Findings
- UBT251 produced up to 19.7% mean body weight loss at 24 weeks versus 2.0% for placebo.
- Placebo-adjusted weight reduction reached 17.7% in the highest-dose group — among the largest reported for any obesity drug.
- Improvements spanned waist circumference, BMI, blood pressure, lipids, and glycemic markers simultaneously.
- The triple GLP-1/GIP/glucagon mechanism may outperform dual agonists by adding thermogenic glucagon activity.
- Safety profile was acceptable; gastrointestinal side effects were mild-to-moderate and consistent with the drug class.
Methodology
Multicenter, randomized, double-blind, placebo-controlled phase 2 trial in 205 adults with overweight or obesity (without type 2 diabetes) across multiple Chinese hospital sites. Participants received once-weekly UBT251 at 2 mg, 4 mg (two starting dose variants), or 6 mg, or placebo for 24 weeks. The primary endpoint was least-squares mean percentage change in body weight at week 24.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access. The trial was conducted exclusively in a Chinese population over 24 weeks, limiting long-term durability data and broader generalizability. Industry co-funding and authorship involvement from both the sponsoring company and Novo Nordisk introduce potential conflicts of interest.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: